India, Sept. 11 -- Shares of Travere Therapeutics Inc. (TVTX) touched a 52-week high of $68.59 yesterday, reflecting the meaningful progress made across its key growth areas and the continued momentum in its business.
This biopharmaceutical company is focused on developing best-in-class therapies for rare kidney and metabolic diseases to address significant unmet medical needs. Its flagship product, Filspari, is approved for use in the treatment of primary immunoglobulin A nephropathy and focal segmental glomerulosclerosis. The company also markets tiopronin products (Thiola and Thiola EC), approved for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine, resulting in the formation of...